Desmond Padhi

2.4k total citations · 1 hit paper
31 papers, 1.8k citations indexed

About

Desmond Padhi is a scholar working on Nephrology, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Desmond Padhi has authored 31 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Nephrology, 9 papers in Pediatrics, Perinatology and Child Health and 8 papers in Molecular Biology. Recurrent topics in Desmond Padhi's work include Parathyroid Disorders and Treatments (10 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Bone health and treatments (6 papers). Desmond Padhi is often cited by papers focused on Parathyroid Disorders and Treatments (10 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Bone health and treatments (6 papers). Desmond Padhi collaborates with scholars based in United States, United Kingdom and Canada. Desmond Padhi's co-authors include Liang Fang, Graham Jang, Brian Stouch, Edward L. Posvar, Robert Z. Harris, Edward Lee, Henry G. Bone, Geoffrey A. Block, Margaret Salfi and Melton B. Affrime and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Journal of Bone and Mineral Research.

In The Last Decade

Desmond Padhi

31 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

2010 603 citations Desmond Padhi, Graham Jang et al. Journal of Bone and Mineral Research profile →

Peers

Countries citing papers authored by Desmond Padhi

Since Specialization

Citations

This map shows the geographic impact of Desmond Padhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Desmond Padhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Desmond Padhi more than expected).

Fields of papers citing papers by Desmond Padhi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Desmond Padhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Desmond Padhi. The network helps show where Desmond Padhi may publish in the future.

Co-authorship network of co-authors of Desmond Padhi

This figure shows the co-authorship network connecting the top 25 collaborators of Desmond Padhi. A scholar is included among the top collaborators of Desmond Padhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Desmond Padhi. Desmond Padhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe 2015 ·Cancer Chemotherapy and Pharmacology ·Bingbing Yang, Phuong K. Morrow, (unknown), Michael Moxness, Desmond Padhi	28
2	Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer 2014 ·The Journal of Clinical Endocrinology & Metabolism ·Desmond Padhi, Celestia S. Higano, Neal D. Shore, Paul Sieber, Erik Rasmussen, Matthew Ryan Smith	63
3	Effects of Calcium Carbonate, Sevelamer Hydrochloride or Pantoprazole on the Pharmacokinetics of Cinacalcet 2014 ·Clinical Drug Investigation ·Desmond Padhi, Robert Z. Harris, John T. Sullivan	3
4	A single-dose study of denosumab in patients with various degrees of renal impairment 2012 ·Journal of Bone and Mineral Research ·Geoffrey A. Block, Henry G. Bone, Liang Fang, Edward Lee, Desmond Padhi	244
5	An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects 2012 ·Pediatric Nephrology ·Desmond Padhi, Craig B. Langman, Sahar Fathallah-Shaykh, Bradley A. Warady, Isidro B. Salusky, Edward Lee, Christine Wang, Edward L. Posvar	15
6	A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women 2011 ·Bone ·Yuji Kumagai, Tomoko Hasunuma, Desmond Padhi	26
7	Clinical Pharmacokinetic and Pharmacodynamic Profile of Cinacalcet Hydrochloride 2009 ·Clinical Pharmacokinetics ·Desmond Padhi, Robert Z. Harris	84
8	Cinacalcet Does Not Affect the Activity of Cytochrome P450 3A Enzymes, a Metabolic Pathway for Common Immunosuppressive Agents 2008 ·Drugs in R&D ·Desmond Padhi, (unknown), Maurice G. Emery	8
9	Pharmacokinetics and Pharmacodynamics of Cinacalcet in Hepatic Impairment 2008 ·Clinical Drug Investigation ·Desmond Padhi, Robert Z. Harris, Margaret Salfi, Robert J. Noveck, John T. Sullivan	20
10	The Pharmacokinetics of Cinacalcet are Unaffected Following Consumption of High- and Low-Fat Meals 2007 ·American Journal of Therapeutics ·Desmond Padhi, Margaret Salfi, Robert Z. Harris	20
11	Pharmacokinetics of Cinacalcet Hydrochloride When Administered with Ketoconazole 2007 ·Clinical Pharmacokinetics ·Robert Z. Harris, Margaret Salfi, John T. Sullivan, Desmond Padhi	30
12	Cinacalcet Does Not Affect the??Pharmacokinetics or Pharmacodynamics of Warfarin 2007 ·Drugs in R&D ·Desmond Padhi, John T. Sullivan	3
13	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl 2006 ·European Journal of Clinical Pharmacology ·Robert Z. Harris, Margaret Salfi, (unknown), David Hoelscher, Desmond Padhi	18
14	An Extended Terminal Half-Life for Darbepoetin Alfa 2006 ·Clinical Pharmacokinetics ·Desmond Padhi, Liyun Ni, Blaire Cooke, Rafael Marino, Graham Jang	31
15	No Effect of Renal Function or Dialysis on Pharmacokinetics of Cinacalcet (Sensipar??/Mimpara??) 2005 ·Clinical Pharmacokinetics ·Desmond Padhi, Robert Z. Harris, Margaret Salfi, John T. Sullivan	21
16	Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily 2004 ·American Journal of Kidney Diseases ·Robert Z. Harris, Desmond Padhi, Thomas Marbury, Robert J. Noveck, Margaret Salfi, John T. Sullivan	59
17	METABOLISM AND DISPOSITION OF CALCIMIMETIC AGENT CINACALCET HCL IN HUMANS AND ANIMAL MODELS 2004 ·Drug Metabolism and Disposition ·Gondi Kumar, (unknown), Leszek Poppe, (unknown), Mark Gohdes, (unknown), Desmond Padhi, Lorin Roskos	48
18	Desloratadine Demonstrates Dose Proportionality in Healthy Adults After Single Doses 2002 ·Clinical Pharmacokinetics ·Samir K. Gupta, Christopher Banfield, Melton B. Affrime, (unknown), Mitchell N. Cayen, Jerry Herron, Desmond Padhi	21
19	Oral Bioavailability of Desloratadine Is Unaffected by Food 2002 ·Clinical Pharmacokinetics ·Samir K. Gupta, Christopher Banfield, Melton B. Affrime, Thomas Marbury, Desmond Padhi, Paul Glue	26
20	Desloratadine Has No Clinically Relevant Electrocardiographic or Pharmacodynamic Interactions with Ketoconazole 2002 ·Clinical Pharmacokinetics ·Christopher Banfield, Jerry Herron, Anther Keung, Desmond Padhi, Melton B. Affrime	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact